Vertex maintained by Merrill at neutral

Vertex Pharmaceuticals Inc. was maintained by Merrill Lynch analyst Hari Sambasivam at a neutral rating following second-quarter results, noting the company reduced its guidance for a wider net loss in 2005 of $140 million to $150 million from $125 million to $135 million. Vertex shares Thursday were down $0.72, or 4.25%, at $16.24 on volume of 1,929,659 shares versus the three-month running average of 1,924,460 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.